Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Tiotropium/Olodaterol Improved Lung Function in Steroid-Free Patients With COPD

Publish date:: November 10, 2019

Key clinical point: In patients with moderate to severe chronic obstructive pulmonary disease (COPD), treatment with tiotropium/olodaterol combination therapy improves outcomes, compared with tiotropium alone.

Major finding: Patients not receiving inhaled corticosteroids who received tiotropium/olodaterol had a significantly greater improvement in trough forced expiratory volume in 1 second response by week 12 of treatment, compared with patients receiving tiotropium alone (0.054 L; P less than .0001).

Study details: Post hoc analysis of pooled data from the TONADO 1 and 2 and OTEMTO 1 and 2 trials included a total of 1,596 patients with COPD.

Disclosures: Dr. Calverley reported grants and personal fees from GlaxoSmithKline; personal fees from AstraZeneca, Recipharm, and Zambon; and personal and other fees from Boehringer Ingelheim outside the submitted work.

Citation:

Calverley PM et al. CHEST 2019. Abstract, doi: 10.1016/j.chest.2019.08.310.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

Osteoporosis prevalence in PsA similar to general population,

Annual WCC visits significantly limit asthma worsening,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Microplastics permeate human placentas,

Must Reads in Pulmonology

Does daily inhaler monitoring improve asthma outcomes in children?,

COVID-19–induced drop in first measles vaccinations sparks resurgence concerns,

E-cigarette use tied to increased COPD, asthma risk,

Obesity, hypoxia predict severity in children with COVID-19,

Telehealth finds acceptance among patients with CF, clinicians,